ZymoGenetics Inc. shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb Co. offered on Wednesday, September 8, aren't likely to get one. [See Deal] ( See "From HCV Partner to Acquirer, BMS Makes $885 Million Offer for ZymoGenetics," "The Pink Sheet" DAILY , September 7, 2010 Also see "From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics" - Pink Sheet, 7 September, 2010..)
It's a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it. (...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?